4D Molecular Therapeutics (NASDAQ:FDMT) shares surged over 60% premarket after the company reported positive interim data for its eye disease drug, 4D-150.
Data consists of 24-week results from a randomized Phase 2 Dose Expansion cohort of the PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients with severe disease activity and a high treatment burden.
The drug was found to be well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up, with no significant inflammation observed.
High dose 4D-150 (3E10 vg/eye) resulted in an 89% reduction in the annualized anti-VEGF injection rate.
The company plans to initiate a Phase 3 clinical trial in the first quarter of 2025.
Image and article originally from seekingalpha.com. Read the original article here.